Introduction {#S1}
============

The proteolytic cleavage, or "shedding," of the extracellular region (ectodomain) of transmembrane proteins is an important mechanism for the regulation of leukocyte development and function. Shedding can initiate intracellular signal transduction *via* the cell-associated cleavage fragment (e.g., Notch signaling to drive cell fate decisions), downregulate signaling or adhesion that requires cell surface receptor expression, or activate paracrine signaling through the release of growth factors, cytokines, and chemokines ([@B1]). The ADAMs (a disintegrin and metalloproteinases) are one of the main proteinase families that function as sheddases and can be regarded as "molecular scissors." A total of 22 ADAM genes have been identified in humans, of which 12 (ADAM8, 9, 10, 12, 15, 17, 19, 20, 21, 28, 30, and 33) are active proteases with the consensus sequence (HExGHxxGxxHD) required for Zn^2+^-dependent protease activity ([@B1]).

The "Molecular Scissor" ADAM10 {#S2}
==============================

One of the best-characterized ADAMs is ADAM10, due to its essential role in ligand-dependent cleavage of Notch proteins to initiate Notch signaling ([@B2]). Indeed, ADAM10-knockout mice die at embryonic day 9.5, phenocopying double knockout mice for two of the four Notch proteins, Notch 1 and 4 ([@B3], [@B4]). ADAM10 has an N-terminal signal sequence, an inhibitory prodomain, a metalloproteinase domain, followed by disintegrin, cysteine-rich, transmembrane, and cytoplasmic domains (Figure [1](#F1){ref-type="fig"}). The prodomain is removed by proprotein convertases during biosynthesis to generate a mature sheddase ([@B5]). The first crystal structure of the mature ADAM10 ectodomain suggests that the metalloprotease exists in a closed conformation in which the cysteine-rich domain partially occludes the catalytic site, but with the catalytic site in position to cleave substrates close to the plasma membrane ([@B6]). ADAM10 has at least 40 substrates, including amyloid precursor protein ([@B7]), cellular prion protein ([@B8]), cadherins ([@B9]--[@B11]), and the platelet-activating collagen/fibrin receptor GPVI ([@B12], [@B13]). ADAM10 has a number of substrates that are expressed by leukocytes, or which impact on leukocyte function, including the low-affinity IgE receptor CD23 ([@B14], [@B15]), the endothelial cell--cell adhesion molecule vascular-endothelial (VE)-cadherin ([@B11]), the B-cell costimulatory molecule ICOS ligand ([@B16]), B-cell homeostasis proteins transmembrane activator and CAML interactor (TACI) ([@B17]) and BAFF receptor (BAFFR) ([@B18]), and triggering receptor expressed on myeloid cells 2 (TREM2) ([@B19], [@B20]). ADAM10 has been implicated in myriad immune diseases including T-cell acute lymphoblastic leukemia (T-ALL), asthma, atherosclerosis, and Alzheimer's disease ([@B2]).

![Six ADAM10 scissors: Tspan14 and Tspan5 may be important for Notch activation in immune cells. **(A)** A schematic representation of a TspanC8 and ADAM10. **(B)** A model figure to show the six different TspanC8/ADAM10 complexes, which have different subcellular localizations, distinct substrate specificities, and may have different ADAM10 conformations. Notch cleavage is initiated following engagement with a Notch ligand on another cell (1), which induces a conformational change that we hypothesize allows cleavage by a Tspan14/ADAM10 or Tspan5/ADAM10 scissor (2), followed by intramembrane cleavage by γ-secretase (3), to release the intracellular domain to act as a transcription factor and drive cell fate decisions (4). Tspan10 has also been implicated in Notch activation, but its relatively low expression by immune cells suggests no substantial role in these cells. N-linked and O-linked glycosylation sites are indicated by filled ovals and short lines, respectively.](fimmu-09-01451-g001){#F1}

Tetraspanins as "Membrane Organizers" {#S3}
=====================================

The tetraspanins are a superfamily of transmembrane proteins expressed in multicellular eukaryotes. They are characterized by four transmembrane domains and small and large extracellular loops (Figure [1](#F1){ref-type="fig"}), the latter containing structurally important cysteine residues. Mammals express 33 tetraspanins and each cell type has a distinct repertoire of tetraspanins ([@B21]); leukocytes express at least 20 tetraspanins ([@B22]). Tetraspanins are "membrane organizers" that form dynamic nanoclusters ([@B21]). Visualization of tetraspanins CD37, CD53, CD81, and CD82 on human B-cells and dendritic cells, by super-resolution microscopy, suggests that approximately 10 tetraspanins of a single type cluster together into individual nanodomains ([@B23]). Tetraspanins also associate directly with specific non-tetraspanin proteins, termed "partner proteins," to regulate their intracellular trafficking, clustering, lateral mobility, and compartmentalization ([@B21]). Relatively well-studied tetraspanin--partner interactions are tetraspanin CD151 with the laminin-binding integrins ([@B24]), tetraspanin CD81 with the B-cell co-receptor CD19 ([@B25]), and Tspan12 with the Wnt/Norrin receptor Frizzled-4 ([@B26]). In each case, tetraspanin mutations yield phenotypes that are consistent with impaired partner protein function. For example, in CD81-deficient humans and mice, CD19 fails to traffic to the B-cell surface and antibody generation is impaired ([@B25]). The recently published crystal structure of full-length CD81, which is the first such structure for a tetraspanin, shows CD81 to be cone shaped with an intramembrane cholesterol-binding cavity within the transmembranes ([@B27]). Molecular dynamics simulations suggest that CD81 may exist in two different conformations, a closed conformation when cholesterol is present, and an open conformation when cholesterol is absent, in which the large extracellular loop swings upwards ([@B27]). Therefore, tetraspanins could function as "molecular switches" that control the activity of their partner proteins through cholesterol-regulated conformational change.

TspanC8 Tetraspanins Regulate ADAM10: The "Six Scissor" Hypothesis {#S4}
==================================================================

In 2012, we and others showed that ADAM10 interacts with six tetraspanins that are closely related by protein sequence: Tspan5, Tspan10, Tspan14, Tspan15, Tspan17, and Tspan33 ([@B28]--[@B30]). We termed these the TspanC8 subgroup due to the eight cysteine residues in their large extracellular loops ([@B28], [@B29]); other tetraspanins have four, six, or seven cysteines. The TspanC8s are essential for promoting ADAM10 exit from the endoplasmic reticulum, its subsequent maturation in the Golgi through removal of the prodomain, and trafficking to the cell surface or other membrane compartments ([@B28]--[@B30]). The functional association between TspanC8s and ADAM10 has been demonstrated in TspanC8-knockout mice ([@B29], [@B31]) and the fruit fly *Drosophila* ([@B28]), and is reinforced by recent data demonstrating reciprocal regulation of Tspan5 exit from the endoplasmic reticulum by ADAM10 ([@B32]). Moreover, emerging evidence indicates that each TspanC8 can target ADAM10 to different subcellular localizations and to different substrates, and ADAM10 may adopt distinct conformations dictated by the associated TspanC8 ([@B28], [@B32]--[@B35]). For example, we and two other groups reported Tspan15 as the only TspanC8 to promote ADAM10 cleavage of neuronal (N)-cadherin ([@B30], [@B33], [@B34]). These *in vitro* data are supported by data from the recently characterized Tspan15-deficient mouse, which has strikingly reduced N-cadherin cleavage in the brain, despite only a subtle decrease in mature ADAM10 expression ([@B31]). ADAM10 shedding of Notch is promoted by Tspan5, Tspan10, and Tspan14 (Figure [1](#F1){ref-type="fig"}), but not by Tspan15 and 33 ([@B28], [@B32], [@B33], [@B36]). In addition, we have shown Tspan5 and Tspan17 to regulate VE-cadherin expression on endothelial cells ([@B35]). Taking these data together, we now propose that ADAM10 should be regarded as six different TspanC8/ADAM10 scissor complexes, rather than a single scissor ([@B37], [@B38]). This idea has implications for therapeutic targeting of ADAM10, which may be impractical due to toxic side effects. However, targeting one of the TspanC8/ADAM10 complexes, *via* the tetraspanin, may minimize toxicity while enabling substrate- and disease-specific targeting.

We and others have recently reviewed our current understanding of how TspanC8s regulate ADAM10 ([@B37]--[@B39]). In this review, we will analyze and present published RNA-Seq transcriptomic data for TspanC8 expression in different leukocyte subsets. We will discuss these expression profiles in the context of our current knowledge of ADAM10's role in the development and function of T-cells, B-cells, and myeloid cells.

Regulation of T-Cell Development and Transmigration by ADAM10 and TspanC8s {#S5}
==========================================================================

Two publications have shown that ADAM10 is important for normal T-cell development, most likely through regulation of Notch signaling ([@B40], [@B41]). In the first, the embryonic lethality of ADAM10-knockout mice was circumvented by the generation of transgenic mice that express dominant negative ADAM10 under the control of the T-cell-specific Lck promoter ([@B40]). The dominant negative ADAM10 construct yields a similar phenotype to T-cell-specific deletion of Notch1, the Notch family member with the major role in thymocyte development. Thymocyte numbers are reduced by 60--90% due to a partial block in the CD4/CD8 double negative to double positive transition, with accompanying reduction in expression of T-cell receptor (TCR) β ([@B40]). Defective Notch signaling is the probable mechanism, since expression of Notch-responsive genes is partially reduced, and partial rescue is achieved by transgenic overexpression of the Notch ligand Delta-1, or a dominant active form of Notch1, in thymocytes. The dominant negative construct lacks the metalloproteinase domain and is expressed at several-fold higher levels than endogenous ADAM10 ([@B40]); one mechanism of action may be the sequestration of endogenous TspanC8s, since we have shown such a construct to interact with TspanC8s ([@B34]). In the second publication, conditional T-cell-specific ADAM10-knockout mice were generated by crossing ADAM10 floxed mice with mice expressing Cre recombinase driven by the Lck promoter ([@B41]). This model phenocopies T-cell-specific Notch1 deletion in showing a twofold to threefold reduction in thymocyte numbers, due to a partial block in development from the double negative to double positive stage. There is reduced expression of Notch target genes but, unlike the dominant negative ADAM10 model, no defect in TCRβ expression is observed ([@B41]).

The most highly expressed TspanC8 in human and mouse T-cells is Tspan14, followed by Tspan5 and Tspan17; Tspan15 is also expressed by human T-cells but not mouse (Figures [2](#F2){ref-type="fig"}A,B). However, it is important to note that such publically available transcriptomic data have not been independently validated, nor have the expression profiles been confirmed using validated antibodies. Nevertheless, since both Tspan14 and Tspan5 promote Notch signaling ([@B28], [@B32], [@B33]), we hypothesize that Tspan14/ADAM10 will have a major role in thymocyte development *via* activation of Notch1, while Tspan5/ADAM10 may have a minor role. The future analyses of the respective knockout mice will help to test this hypothesis; the Tspan14-knockout mouse has yet to be made, while the Tspan5-knockout mouse is viable but functionally uncharacterized ([@B32]). It is possible that Tspan14 and/or Tspan5 play a role in the aggressive blood cancer T-ALL. Approximately 50% of T-ALL is driven by activating mutations in Notch1, some of which require ADAM10 for full activation in a ligand-independent manner. Knockdown of ADAM10 reduces Notch signaling and T-ALL proliferation ([@B42]). Targeting Tspan14 or Tspan5 may achieve a similar result, yet without the toxicity of global ADAM10 inhibition. Interestingly, antibody targeting of Tspan5 can impair Notch signaling ([@B32]).

![Leukocytes express ADAM10, but different cell subsets have distinct TspanC8 repertoires. Publically available RNA-Seq data for **(A)** human leukocytes \[Gene Expression Omnibus (GEO) accession GSE51984\], **(B)** mouse T-cell subsets ([@B43]), **(C)** mouse B-cells (GEO accession GSE60927), and **(D)** mouse macrophages, monocytes, and neutrophils (GEO accession GSE59831). Data are presented as reads per kilobase of transcript per million mapped reads (RPKM) **(A,C)**, as length-adjusted values that provide a measure equivalent to RPKM ([@B43]) **(B)**, or as fragments per kilobase of transcript per million mapped reads (FPKM) **(D)**. Error bars represent the SD. Number of samples are as follows: five for panel **(A)**, except for CD34+ peripheral cells (hematopoietic stem cells from the blood) which has one; two for panel **(C)**, except for splenic plasmablasts and bone marrow plasma cells which have one, and splenic plasma cells which have three; and two for panel **(D)**, with the exception of neutrophils which have two.](fimmu-09-01451-g002){#F2}

In addition to Notch proteins, a number of other proteins have been reported to be cleaved by ADAM10 on T-cells: CD40 ligand ([@B44]), Fas ligand ([@B45], [@B46]), LAG-3 ([@B47]), CD44 ([@B48]), and T-cell immunoglobulin and mucin domain 3 (Tim-3) ([@B49]). How important these cleavage events are to T-cell function has yet to be determined, and for CD40 ligand, LAG-3 and Tim-3 is complicated by their additional cleavage by ADAM17 ([@B44], [@B47], [@B49]), an ADAM10-related metalloproteinase.

We have recently reported that endothelial cell-expressed ADAM10 promotes the transmigration (also known as extravasation or diapedesis) of T-cells in an *in vitro* model of inflammation ([@B35]). The mechanism involves ADAM10 regulation of VE-cadherin expression levels, since ADAM10 knockdown results in 50% elevated VE-cadherin expression and delayed transmigration, which is rescued by partial VE-cadherin knockdown to wild-type levels. This promotion of transmigration by endothelial ADAM10 appears restricted to T-cells, since no effects on neutrophils or B-cell transmigration are observed ([@B35]), nor on monocytes in a separate study ([@B50]). Among the TspanC8s, we have previously reported that Tspan14 is the most highly expressed on endothelial cells ([@B29], [@B51]). However, knockdown experiments show that Tspan5 and Tspan17 are the tetraspanins that promote ADAM10 regulation of VE-cadherin ([@B35]). Consistent with this common function, Tspan5 and Tspan17 are the most highly conserved pair of tetraspanins, with 72% protein sequence identity in human ([@B35]). However, it remains to be determined whether this role for Tspan5/17 holds true *in vivo*. Tspan17-knockout mice have yet to be made; ultimately a Tspan5/17 double knockout may be required to overcome functional redundancy.

Regulation of B-Cell Development and Function by ADAM10 and Potential Role for TspanC8s {#S6}
=======================================================================================

An important role for ADAM10 in B-cell development and function has been demonstrated using B-cell-specific ADAM10-knockout mice, made by crossing ADAM10 floxed mice with CD19-Cre mice ([@B52]). Early development of B-cells in the bone marrow of these mice is unaltered, with normal numbers of pro-, pre-, and immature B-cell populations. B1 cell numbers in the peritoneal cavity are also normal. However, ADAM10-knockout immature B-cells entering the spleen fail to develop into marginal zone B-cells; these cells act as a first line of defense by rapid antibody generation against blood-borne pathogens that become trapped in the spleen. By contrast, follicular zone B-cell numbers in the spleen are slightly elevated. The mechanism underlying defective marginal zone B-cell development in the absence of ADAM10 appears to be defective Notch2 activation ([@B52]), and consistent with this, B-cells express relatively high levels of Notch2 and low levels of Notch 1, 3, and 4, and Notch2 is critical for development of marginal zone but not follicular B-cells ([@B53]--[@B55]).

B-cell-specific ADAM10-knockout mice have a striking reduction in antibody responses following immunization, associated with impaired germinal center formation in secondary lymphoid tissues ([@B56]). The mechanism responsible appears to be the upregulated expression of TNFα, a pro-inflammatory cytokine which is important for the maintenance of lymphoid tissue architecture, and ADAM17, which sheds TNFα ([@B57]). How ADAM10-deficiency leads to ADAM17 and TNFα upregulation in B-cells remains unknown. To investigate the function of ADAM10-knockout plasma cells in the context of normal germinal centers, ADAM10 floxed mice were crossed with IgG1-Cre mice to delete ADAM10 post-isotype switching. Antibody responses are strikingly reduced, despite normal plasma cell numbers ([@B58]). This may be due to elevated expression of ICOS ligand, a recently identified ADAM10 substrate, on ADAM10-knockout B-cells ([@B16]). The engagement of ICOS ligand with its receptor ICOS on T-cells is required for T-cell-dependent antibody responses. In ADAM10-knockout B-cells, elevated ICOSL causes a substantial reduction in surface ICOS by promoting its internalization ([@B16]), thus providing a mechanism for impaired antibody responses.

With the possible exception of Notch2, the best-studied ADAM10 substrate on B-cells is CD23, the low-affinity IgE receptor, which regulates allergic and inflammatory responses ([@B14], [@B15]). Indeed, on ADAM10-knockout B-cells, CD23 expression is increased approximately threefold, while soluble CD23 levels in plasma are substantially reduced ([@B52]). In an IgE-dependent asthma model, B-cell-specific ADAM10-knockout mice have strikingly reduced signs of allergic inflammation in the lung ([@B59]). Allergic patients and allergy-prone Th2 mice have increased expression of ADAM10 on B-cells and increased soluble CD23 and IgE levels in plasma ([@B60]). Although the regulation of IgE expression by CD23 is complex and not fully understood, these data have lead the authors to propose ADAM10 as a therapeutic target for asthma ([@B59]).

ADAM10 is emerging as a regulator of the BAFF--APRIL system which controls B-cell homeostasis. The two ligands are BAFF and APRIL, while the three receptors are B-cell maturation antigen, TACI, and BAFFR, the latter of which binds BAFF but not APRIL. ADAM10 can shed TACI to release a soluble ectodomain that acts as a decoy receptor, binding to BAFF and APRIL and so inhibiting survival of B-cells ([@B17]). In addition, cell survival can be reduced by ADAM10 or ADAM17 shedding of BAFFR ([@B18]).

In human B-cells, Tspan33 expression is highest, followed by Tspan14, Tspan17, and then Tspan5 (Figure [2](#F2){ref-type="fig"}A). In mouse, Tspan14 expression is highest, followed by Tspan5, Tspan15, and Tspan17, while Tspan33 expression is minimal (Figure [2](#F2){ref-type="fig"}C). Therefore, Tspan14 is likely to be the main regulator of Notch2 in B-cells, with a less important role for Tspan5. A role for TspanC8s in regulating CD23 shedding has not been reported, but Tspan5, Tspan14, Tspan17, and/or Tspan33 are candidates; this is important work for the future, because such a tetraspanin is a potential therapeutic target for asthma. Tspan33 expression in human B-cells has been confirmed at the protein level ([@B61]), but the ADAM10 substrates that it regulates have not been investigated.

Regulation of Myeloid Cell Function by ADAM10 and Potential Role for TspanC8s {#S7}
=============================================================================

Dendritic cell-specific ADAM10-knockout mice have been generated by crossing ADAM10 floxed mice with CD11c-Cre mice ([@B62]). These mice have strikingly impaired Th2 responses, but Th1 and Th17 responses are unaffected. As a consequence, the mice are protected from IgE-mediated anaphylaxis and allergic lung inflammation. This appears to be due to defective Notch signaling, since rescue is observed by transgenic expression of the Notch1 intracellular domain, and dendritic cell-specific Notch1-knockout mice have a similar phenotype ([@B62]). Our RNA-Seq analyses have found Tspan14 to be most highly expressed in human dendritic cells, with lower expression of Tspan17 and Tspan33 (data not shown). Therefore, Tspan14 is likely to be important in dendritic cells for Notch signaling.

Specific knockout of ADAM10 in myeloid cells has been investigated by crossing ADAM10 floxed mice with LysM-cre mice ([@B63]). This does not achieve complete knockout in myeloid cells, but surface levels of ADAM10 on bone marrow-derived macrophages are reduced by 85%. No major abnormalities in the mice are observed, and leukocyte populations are present in normal numbers. However, ADAM10-knockout results in a reduced inflammatory phenotype in macrophages and a reduced capacity to migrate and to degrade extracellular matrix ([@B63]). Macrophages play a central role in the initiation and progression of the inflammatory disease atherosclerosis, and can take up lipids to become pro-inflammatory foam cells within atherosclerotic plaques. To investigate the role of macrophage ADAM10 in this disease, bone marrow from myeloid-specific ADAM10-knockout mice was transplanted into atherosclerosis-prone low-density lipoprotein receptor knockout mice. Consistent with a less inflammatory macrophage phenotype, atherosclerotic plaques appear more stable, with higher collagen content, although plaque size is similar to wild type ([@B63]). Nevertheless, this has important implications for human disease; stable plaques are less susceptible to the rupture that causes thrombosis, vessel occlusion, and heart attack or stroke. Interestingly, Notch signaling promotes an inflammatory macrophage phenotype, and blockade of Notch signaling in an atherosclerosis model reduces atherosclerosis development while increasing plaque stability ([@B64]). Macrophages express relatively high levels of the Notch-promoting Tspan14 (Figures [2](#F2){ref-type="fig"}A,D), highlighting the macrophage Tspan14/ADAM10 complex as a potential therapeutic target for maintaining plaque stability in atherosclerosis.

An additional study generated mice with leukocyte- and myeloid-specific ADAM10 deficiency by crossing floxed ADAM10 mice with Vav-Cre and LysM-Cre mice, respectively. In an inflammatory lung model, neutrophil and monocyte recruitment are reduced by approximately 50% in the absence of ADAM10 ([@B65]). The underlying mechanism is not clear. Tspan14 appears to be the only TspanC8 expressed by human granulocytes and is also highly expressed by mouse neutrophils, which have relatively weak Tspan5 expression (Figures [2](#F2){ref-type="fig"}A,D). Therefore, Tspan14/ADAM10-induced Notch activation may potentially promote neutrophil inflammatory responses.

Finally, the scavenger receptor TREM2 has been recently identified as an ADAM10 substrate with a potential role in Alzheimer's disease ([@B19], [@B20]). TREM2 is expressed on macrophages, microglia, osteoclasts, and dendritic cells. A rare H157Y variant of TREM2 is associated with increased risk of Alzheimer's disease; amino acid 157 is at the cleavage site for ADAM10, and H157Y is shed more readily. The loss of TREM2 renders macrophages less phagocytic, and the authors propose that this renders the individual more prone to Alzheimer's disease ([@B19], [@B20]). It will be interesting to determine if any macrophage-expressed TspanC8, namely Tspan5, Tspan14, Tspan17, or Tspan33, can promote TREM2 cleavage, and could thus be considered a therapeutic target for TREM2-associated Alzheimer's disease.

Concluding Remarks {#S8}
==================

The six scissor hypothesis suggests that ADAM10 should be studied in the context of its regulatory tetraspanins. In leukocytes, the relatively high expression of Tspan14, together with its capacity to promote Notch activation, suggest that the Tspan14/ADAM10 complex may be critical for leukocyte development and function. The future analyses of cells and mice deficient in Tspan14, and other TspanC8s, will determine which scissor cleaves which substrates. This may direct therapeutic targeting of individual TspanC8/ADAM10 complexes, using antibodies or small molecules, to modulate a specific substrate while avoiding the toxicity of global ADAM10 targeting. Such an approach could provide new treatments for ADAM10-associated diseases, including T-ALL, asthma, atherosclerosis, and Alzheimer's disease.
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